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Abstract 
 
The observation that patients with type 2 diabetes tend to have larger 
glomeruli than patients with type 1 diabetes was first made more than 10 
years ago. It has also been noted that type 2 diabetic patients with 
nephropathy often have more heterogeneous renal function and structure 
than type 1 patients. However, whether these observations are linked or have 
any bearing on the progression of nephropathy in the two types of diabetes 
remains uncertain. Here we put forward several hypotheses as to why 
glomerular volume in type 1 differs from that in type 2 diabetes. We suggest 
that although type 1 and type 2 diabetic patients appear to progress through 
similar stages of diabetic nephropathy, the route they take may differ. 
Differences in the way in which the glomeruli respond to the diabetic milieu 
may enable some type 2 diabetic patients to preserve their filtration surface in 
the face of an expanding mesangium.  
 
Keywords: Diabetic nephropathy; Glomerular filtration rate; Glomerular 
volume; Proteinuria 
Abbreviations:  MGV  Mean glomerular volume 
   GBM Glomerular basement membrane 
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Introduction 
Nephropathy in both type 1 and type 2 diabetes is characterised by 
proteinuria, declining GFR and increasing blood pressure [1, 2]. The 
development of glomerular and interstitial lesions is also common to the two 
types of diabetes [3-6]. However, the reported rate of progress varies, 
particularly in type 2 diabetic patients, where the decline in GFR can range 
from +3.1 to -22.0 ml min-1 year-1 [2, 7-9]. In type 1 diabetic patients, the 
average rate of decline is 10 ml min-1 year-1 in those with poorly controlled 
blood pressure and 4.8 ml min-1 year-1 in those with good blood pressure 
control [10].  
We and others have shown that structural–functional relationships are similar 
in type 1 and 2 diabetic patients with clinical proteinuria [4, 11]. However, 
there is greater heterogeneity of structural lesions and GFR in both 
microalbuminuric and proteinuric type 2 diabetic patients [4, 8, 12, 13]. Some 
type 2 diabetic patients have a relatively well preserved GFR despite 
increased proteinuria and blood pressure; this may be related to the more 
pronounced glomerular enlargement that is seen in these patients [4]. 
Glomerular enlargement is a well recognised feature of diabetes and has 
been noted at both early (microalbuminuric) and late (proteinuric) stages of 
nephropathy [14]. There is some debate as to whether this enlargement is an 
adaptive response, or whether glomerular enlargement itself accelerates 
glomerulopathic change [15].  
In this paper we bring together data from previous studies examining 
glomerular structure in type 1 and type 2 diabetic patients with albuminuria. 
Our aim is to explore whether there were any differences in structure that 
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might be related to the observed functional contrasts and to propose 
hypotheses for the previously observed differences in glomerular volume in 
type 1 and type 2 diabetic patients. 
 
Evidence of differences in glomerular volume in type 1 and type 2 
diabetic patients 
Mean glomerular volume (MGV) has been estimated in a number of studies in 
both type 1 and type 2 diabetic patients. However, there are no studies where 
a direct comparison between the two groups has been made. Østerby et al. 
measured glomerular volume in type 2 patients and compared the results with 
those from previously reported type 1 patients [4]. The MGV values were 
much higher in the type 2 than type 1 diabetic patients (mean [CV]: 6.2 [0.42] 
×106 vs 2.4 [0.26] ×106 µm3). In our own studies we have reported values for 
MGVs that are significantly higher in type 2 [16] than type 1 [17] (5.5 [0.22] 
×106  vs 4.0 [0.30] ×106 µm3, p < 0.001) diabetic patients. Studies in Pima 
Indians show that MGV is significantly increased as nephropathy progresses, 
with values in resin-embedded tissue as high as 8.5 × 106 µm3 being reported 
[18]. 
Variations in tissue preparation can have a significant effect on glomerular 
volume and therefore comparisons between groups whose samples were 
processed at different times must be made with caution. However, although 
the biopsies from the Østerby study were all treated the same way, they were 
paraffin embedded, which can cause significant tissue shrinkage. The 
samples from biopsies from our studies were all embedded in epoxy resin, 
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which limits tissue shrinkage [19], and all glomerular volumes were measured 
using the Cavalieri method [20] . 
 
Is glomerular enlargement due to mesangial expansion? 
Glomerular enlargement occurs in many disease states, including diabetes, 
and may be either a compensatory or deleterious response [21-23]. It is 
equally possible that glomerular enlargement does not have a deleterious 
effect per se, but is simply a consequence of mesangial matrix accumulation 
and the result, not the cause, of disease progression.  
In order to determine what structural parameters contribute to the increase in 
glomerular volume, we studied both type 1 [17] and type 2 [6, 16] diabetic 
patients. The clinical characteristics of the patients are shown in Table 1 and 
the structural parameters in Table 2. 
The characteristic structural changes seen in diabetic patients with 
nephropathy, i.e. mesangial expansion, increased mesangial matrix and 
glomerular basement membrane (GBM) thickening, are present in both 
groups of patients when compared with non-diabetic subjects. There are no 
significant differences in these variables between the two types of diabetes, 
and glomerular enlargement is evident in both. Both show a correlation 
between mesangial volume fraction and proteinuria (type 1: r = 0.55, p < 
0.001; type 2: r = 0.60, p = 0.019). However, only the type 1 diabetic patients 
show any correlation between MGV and proteinuria (r = 0.44, p = 0.006), 
mesangial volume fraction (r = 0.48, p < 0.001) or GBM width (r=0.33, p = 
0.019). In the type 1 patients the increase in MGV appears to be due to an 
increase in solid components, i.e. cells and matrix, whereas the type 2 
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diabetic patients also show increases in capillary length. This suggests that 
glomerular enlargement in the type 1 patients may be a direct result of an 
expanding mesangium, whereas it may represent different adaptive 
responses in the type 2 patients. 
 
Is glomerular enlargement a compensatory mechanism? 
In diabetes, glomerular enlargement may ameliorate the progression of 
nephropathy. The glomerulus may enlarge in order to maintain filtration 
surface area in the face of an expanding mesangium or as a result of a 
reduction in glomerular number due to occlusion—the remnant glomeruli 
compensating for the loss [24]. We found no significant difference in the 
percentage of occluded glomeruli between the type 1 and type 2 diabetic 
patients in our series; therefore, glomerular loss due to occlusion seems 
unlikely to account for the differences in glomerular volume.  
However, it is possible that other pathological processes may cause non-
functioning glomeruli. There is a high frequency of glomerulotubular 
abnormalities, including atubular glomeruli, in proteinuric type 1 diabetic 
patients, which may contribute to the decline in GFR [25]. There are no 
published data on type 2 diabetes, but it is possible that there are fewer 
atubular glomeruli resulting in better preservation of GFR; or conversely, that 
there is a higher frequency of atubular glomeruli resulting in glomerular 
enlargement of the remaining functional glomeruli and subsequent 
preservation of GFR. This area warrants further investigation. 
Capillary length, and the filtration and mesangio-urinary surface areas are all 
significantly increased in type 2 compared with type 1 patients and non-
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diabetic control subjects, implying that in type 2 diabetes, glomerular 
enlargement is a compensatory mechanism, perhaps to a greater extent than 
in type 1 diabetes. From our current data we hypothesise that the glomeruli 
are compensating for a reduction in filtration surface secondary to mesangial 
expansion. 
 
Is glomerular enlargement different at early and late stages of 
nephropathy? 
In order to compare glomerular volume changes at early and late stages of 
diabetic nephropathy, we grouped our patients into those with 
microalbuminuria (type 1: AER < 200 µg/min; type 2: total protein < 500 mg/ 
24 h) and those with proteinuria (type 1: AER ≥ 200 µg/min; type 2: total 
protein ≥ 500 mg/24 h). Grouping the type 2 diabetic patients on the basis of 
total protein rather than albumin excretion could result in some proteinuric 
patients being wrongly classified as microalbuminuric. However, the 
distinction between microalbuminuria and proteinuria at AER levels close to 
200 µg/min is somewhat arbitrary and it is not possible to discriminate renal 
structure in patients at this interface [8]. 
The difference in MGV between type 1 and type 2 diabetic patients is most 
prominent in microalbuminuric patients (Table 2). In the type 1 diabetic 
patients, MGV is higher in the proteinuric subjects, whereas MGV is increased 
in microalbuminuric type 2 patients and there is no evidence of further 
increases in those with proteinuria. Similar results were found in a group of 
type 2 diabetic patients studied by Dalla Vestra et al. [26]. This suggests that 
glomeruli may have a limited capacity for compensatory enlargement and may 
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reach a stage where they are no longer able to resist mesangial expansion 
and a corresponding decline in filtration surface. This hypothesis is supported 
by the observed relationship between mesangial volume fraction and filtration 
surface seen in proteinuric, but not microalbuminuric, type 2 diabetic patients. 
In contrast, it is the proteinuric type 1 diabetic patients that demonstrate 
increased MGV with corresponding mesangial expansion and loss of filtration 
surface. As the microalbuminuric patients did not show any signs of 
compensatory glomerular enlargement, it is possible that nephropathy in type 
1 diabetic patients might progress more quickly than in type 2 diabetic 
patients. Patients who develop nephropathy after a longer duration of 
diabetes have larger glomeruli than those who develop it after a relatively 
short duration, i.e. ‘fast-trackers’ [27]. Thus, the fast-trackers may have a 
reduced capability for adaptive glomerular enlargement. 
 
Could glomerular enlargement result in increased protein loss? 
The mesangio-capillary surface area (Fig. 1) is significantly increased in both 
type 1 and type 2 diabetic patients, with greater increases seen in the type 2 
diabetic patients. The mesangio-capillary surface is a loose, leaky structure 
and the rapid entry of small tracers (<405 nm) into the mesangium within a 
few minutes of i.v. injection is indicative of a considerable flow of blood 
plasma into this region. It is likely that this fluid is then filtered across the 
mesangio-urinary surface, and contributes to the glomerular filtrate [28]. As 
both mesangio-capillary and mesangio-urinary surface areas are significantly 
increased in the type 2 patients, increased filtration via this pathway could 
contribute towards sustaining GFR at the same time as increasing protein 
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loss, thus explaining in part the paradox of heavy proteinuria with a relatively 
preserved GFR. 
 
Are the differences due to blood pressure? 
Our type 1 diabetic patients were normotensive as part of the entry criteria for 
the ESPRIT Study, whereas the type 2 diabetic patients were hypertensive. 
However, we do not believe this explains the contrasting results. The 
Minneapolis Group have shown that there is no difference in MGV in 
normotensive compared with hypertensive type 1 patients [29] and Table 3 
(Mauer, unpublished data). Thus, it is possible that some factor other than 
blood pressure influences the increase in MGV in the type 2 diabetic patients.  
Despite being normotensive, our type 1 diabetic patients demonstrated the 
characteristic lesions of diabetic glomerulopathy, some to quite an extensive 
degree; other studies have also reported patients with normotension and 
classical glomerular lesions [30, 31].Thus we believe that although this group 
may not be entirely typical, they are representative. 
 
Does age have an influence on glomerular volume? 
Type 2 diabetic patients are significantly older that the type 1 diabetic 
patients. However, glomerular volume decreases with age in normal men [32]. 
Therefore, age is unlikely to explain the differences in glomerular volume seen 
in these patients. 
 
Does duration of diabetes affect glomerular volume? 
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In newly diagnosed type 1 diabetes glomerular volume is increased due to an 
increase in the length and diameter of the capillaries, which is only partially 
normalised after 6 years duration [33]. Our type 1 diabetic patients had a wide 
range of diabetes duration (2-43 years) and there was no correlation between 
duration and glomerular volume. However, we have previously shown that 
type 1 diabetic patients with clinical proteinuria and long duration (24-26 
years) had larger glomeruli than proteinuric patients of shorter diabetes 
duration (14-16 years) [27]. In type 2 diabetic patients the time of onset of 
diabetes is often unknown, but Østerby et al. demonstrated large glomeruli in 
type 2 diabetic patients of known diabetes duration of only 7 years [4]. The 
type 2 diabetic patients in our study were re-biopsied after 2 years and there 
was no significant difference in glomerular volume from baseline to follow-up 
[34]. Thus the exact influence of duration on glomerular volume is unclear, but 
there is no evidence to suggest that it is different in type 1 and type 2 
diabetes. 
 
Are the differences due to increased BMI in type 2 diabetic patients? 
In normal man there is a positive relationship between body surface area and 
glomerular volume [32]. The majority of our type 2 diabetic patients are male 
and have a high BMI, and are therefore likely to have a larger body size than 
the type 1 diabetic patients. Although within each group there is no difference 
in glomerular volume between male and female patients, and within the type 2 
diabetic patients there is no relationship between BMI and glomerular volume, 
the high BMI in the type 2 diabetic patients cannot be discounted as a 
possible contributory cause of increased glomerular volume. 
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Does ethnicity play a role in glomerular volume? 
Ethnicity does influence glomerular volume. Pima Indians have large 
glomeruli even in the absence of diabetes [35], with further enlargement once 
diabetes develops [18]. In addition, a study on renal donors showed that 
glomeruli are larger in African Americans than Europid [36] and an autopsy 
study has shown glomeromegaly in non-diabetic Australian Aborigines 
compared with Australian white subjects [37]. Glomerular enlargement is 
believed to be related to fewer functioning nephrons in these ethnic groups. 
To our knowledge there is no study that has directly compared glomerular 
volume in diabetic patients from different ethnic backgrounds. Values for 
glomerular volume in Pima Indians with type 2 diabetes are greater than those 
measured in our type 2 diabetic patients [18]. However, as the measurements 
were done by two different laboratories using different methodologies it is 
difficult to draw firm conclusions. However, as our studies involved mainly 
Europid patients, differences in ethnic mix cannot explain our observed 
differences between type 1 and type 2 diabetic patients. 
 
Do haemodynamics play a role in glomerular enlargement? 
Although morphometric analysis can demonstrate structural differences 
between the type 1 and type 2 diabetic patients, it cannot tell us much about 
the cause. One possible hypothesis is that there is a variable renal 
haemodynamic response at the onset of diabetes. Early changes in 
glomerular haemodynamics have been implicated in the pathogenesis of 
diabetic glomerulopathy [38]. It has been suggested that the observed loss of 
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autoregulation results in increased glomerular capillary pressure, 
hyperfiltration and glomerular hypertrophy secondary to increases in capillary 
length and surface area. These changes take place within 4 days in the 
diabetic rat [39]. It has been proposed that glomerular hypertrophy secondary 
to changes in pressure and blood flow results in mechanical stress, mesangial 
cell stretch, accumulation of matrix and ultimately to the progression of 
glomerular damage and loss in GFR [40]. This early mechanical stress may 
damage the compensatory mechanism required to resist mesangial 
expansion later in the disease.  
Loss of autoregulation at onset of diabetes is a feature of both type 1 [41] and 
type 2 [42] diabetic patients. However, some type 2 diabetic patients are 
hypertensive at onset and therefore may have a different renal 
haemodynamic response to patients with type 1 diabetes [43, 44]. In 
spontaneously hypertensive rats, a model of essential hypertension, 
glomerular capillary pressure remains normal due to constriction of the 
afferent arteriole [45]. Although glomerular capillary pressure cannot be 
measured directly in man, indirect methods have suggested that in patients 
with essential hypertension the afferent arteriolar resistance is elevated, 
perhaps secondary to hyalinosis, and glomerular capillary pressure is normal 
[46]. Patients with essential hypertension have increased glomerular volumes 
possibly because they also have fewer glomeruli [47]. We hypothesise that 
those type 2 diabetic patients that have essential hypertension, as opposed to 
hypertension caused by diabetic kidney damage, may not have experienced 
any increase in glomerular capillary pressure at onset of diabetes. 
Consequently, there would be no pressure-stretch-induced damage to the 
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compensatory mechanism that permits glomerular enlargement and 
maintenance of the glomerular filtration surface in the face of mesangial 
expansion. We would suggest however, that this ‘protection’ is limited and 
with increasing duration of diabetes, hypertension and nephropathy, patients 
would follow the route of continuing mesangial expansion with increasing loss 
of filtration surface. This would explain the different timing and magnitude of 
glomerular enlargement during the evolution of nephropathy in type 1 and 
type 2 diabetes. 
To test this hypothesis it would be necessary to identify those patients with 
essential hypertension as opposed to hypertension caused by diabetic renal 
disease. Arteriolar hyalinosis is a feature of both diabetic and non-diabetic 
renal disease [48, 49], but in diabetes both the afferent and efferent arterioles 
are affected, whereas in hypertension alone it is restricted to the afferent 
arteriole [50]. It would be extremely difficult to discern patients using this 
criterion. Only natural history studies relating changes in blood pressure to 
arteriolar change can answer this question. 
 
Are differences due to heterogeneity in lesions of type 2 patients? 
It has been suggested that there is more heterogeneity in type 2 
glomerulopathy, with up to 63% of patients demonstrating atypical diabetic 
lesions [12]. However, in unselected biopsy series this proportion is closer to 
10% [51]. We have shown that type 2 diabetic patients with nephropathy have 
structural lesions similar to type 1 diabetic patients and the low CVs suggest 
that there is less heterogeneity than previously thought [11].  
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Conclusion 
Although type 1 and type 2 diabetic patients with nephropathy have similar 
clinical and pathological features, there are some subtle differences that may 
have an important influence on its progression. It is possible that the timing of 
the development of hypertension may play a role. We would suggest that 
there are some type 2 diabetic patients who are able to adapt better to 
developing glomerulopathy and maintain their filtration surface. However, the 
mechanisms involved in maintaining filtration surface may also be responsible 
for the increased proteinuria seen in these patients.  
It is likely that co-morbid conditions, such as hypertension, seen in type 2 
diabetes influence the development of diabetic glomerulopathy and may 
modify the response of the glomerulus to hyperglycaemia. Natural history 
studies that relate changes in blood pressure with structural lesions and 
glomerular volume are required to explore these issues. 
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Table 1. Clinical characteristics of 50 type 1 and 15 type 2 diabetic 
patients with nephropathy. 
 
 
Type 1 Type 2  p 
Number (M/F)   50       (32/18)   15     (13/2)  
Age years   38       (20 – 64)   49     (31 – 64) <0.001 
GFR ml min-1 1.73m-2 
GFR ml min-1 
102       (62 – 162) 
105       (60 – 187) 
 
116     (62 – 169) 
 
 
AER mg/24h a 
Proteinuria mg/24ha 
147       (37 -2302)    
 640     (73 – 3877) 
 
Systolic BP mm/Hg 123       (97 – 147) 147     (120 – 185) <0.001 
Diastolic BP mm/Hg   75       (61 – 89)   85     (67 – 100) <0.001 
 
Data are expressed as mean (range) or amedian (range). 
GFR data in type 1 patients have been corrected for body surface area. 
However, they have also been presented as uncorrected values, as correcting 
GFR for the type 2 patients is likely to result in over-estimation of GFR due to 
the high BMI of these patients (mean BMI 31 ± 3 kg/m2).  
GFR was measured by iohexol clearance in the type 1 diabetic patients and 
creatinine clearance in the type 2 diabetic patients. The correlation between 
these two methods is good except for very high or very low GFRs [52].  
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Table 2. Characteristic glomerular structural parameters of 50 type 1 and 15 type 2 diabetic patients with nephropathy and 14 non-
diabetic subjects. The diabetic subjects have been divided into those with microalbuminuria (M) and those with clinical proteinuria 
(P). 
Type 1 diabetic subjects Type 2 diabetic subjects  
All 
(n = 50) 
M  
(n= 32) 
P  
(n = 18) 
All 
(n = 15) 
M 
 (n = 6) 
P 
(n = 9) 
 
Non-diabetic 
control subjects 
 
p value 
VvMes/Glom 0.32 ± 0.09 0.28 ± 0.08 0.38 ± 0.08 0.35 ± 0.13 0.31 ± 0.10 0.37 ± 0.14 0.18 ± 0.03 <0.001a,b,d 
VvMat/Glom 0.20 ± 0.06 0.18 ± 0.05 0.24 ± 0.06 0.21 ± 0.09 0.18 ± 0.08 0.24 ± 0.10 0.10 ± 0.02 <0.001a,b,d 
GBMwidth 
(nm) 
 578 ± 128  534 ± 108 655  ± 127 593  ± 156  551 ± 121  621 ± 176  361 ± 52 <0.001a,b,d 
Caplength 
(mm) 
29.5 ±  8.4 28.3 ±  8.0 31.7  ± 8.9 44.4  ± 11.2 45.5 ± 9.3 43.7 ± 12.8 25.6 ± 5.9 0.001b,c,e, 0.008f 
Sgbm (mm2) 0.34 ± 0.11 0.34 ± 0.11 0.35 ± 0.11 0.56 ± 0.25 0.62 ± 0.17 0.51 ± 0.29 0.41 ± 0.10 0.049b, 0.001c,e 
SMCap (mm2) 0.24 ± 0.09 0.22 ± 0.08 0.29 ± 0.08 0.33 ± 0.09 0.31 ± 0.10 0.35 ± 0.07 0.12 ± 0.06 <0.001a,b,c, 
0.004d, 0.023e 
SMUr (mm2) 0.16 ± 0.06 0.15 ± 0.06 0.16 ± 0.06 0.28 ± 0.07 0.30 ± 0.09 0.27 ± 0.04 0.14 ± 0.03 <0.001b,c,e,f 
Occluded (%)d  8.3   (0 – 50) 7.8   (0 – 44) 12.1   (0 - 50) 9.7    (0 - 31) 7.1   (6 - 24) 15.5   (0 - 31) N/A NS 
MGV (×106 
 4.0 ± 1.2  3.6 ± 1.1  4.6  ± 1.2  5.5  ± 1.2   5.6 ± 1.3   5.5 ± 1.2   3.2 ± 1.1 0.05a, 0.004d, 
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µm3) <0.001b,c,e 
 
M, microalbuminuric: type 1: AER < 200 µg/min; type 2: total protein < 500 mg/24h 
P, proteinuric: type 1: AER ≥ 200 µg/min; type 2: total protein ≥ 500 mg/24h 
a
 Type 1 (All) diabetic patients compared with non-diabetic control subjects. 
b Type 2 (All) diabetic patients compared with non-diabetic control subjects. 
c
 Type 1 (All) compared with type 2 (All) diabetic patients. 
d
 Microalbuminuric compared with clinically proteinuric type 1 diabetic patients. 
e
 Microalbuminuric type 1 compared with microalbuminuric type 2 diabetic patients. 
f
 Clinically proteinuric type 1 compared with clinically proteinuric type 2 diabetic patients. 
There were no significant differences between microalbuminuric and proteinuric type 2 patients. 
Data are expressed as mean ± SD in or dmedian (range). 
VvMes/Glom, volume fraction of mesangium; VvMat/Glom, volume fraction of matrix; GBM, glomerular basement membrane; Cap 
length, capillary length; Sgbm, filtration surface area; SMCap, mesangio-capillary surface; SMUr, mesangio-urinary surface  
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Table 3.  Data on ten normotensive and ten hypertensive type 1 diabetic 
patients. 
 Normotensive Hypertensive  p  value 
n (male/female) 10 (5/5) 10 (6/4)  
Age (years) 28 ± 7 38 ± 8 0.008 
Duration of diabetes 
(years) 
14 ± 4 21 ± 7 0.02 
GFR (ml min-1 1.73 m-
2) 
112  ± 10 70 ± 30 0.002 
AER (µg/min) a 10 (2-117) 443 (226-869) <0.001 
BP (mmHg)    
 Systolic  134 ± 12 136 ± 12 NS 
 Diastolic  69 ± 8 79 ± 8 0.01 
MGV (×106 µm3) 1.9 ± 0.8 2.2 ± 0.7 NS 
Data are expressed as mean ± SD in or amedian (range). 
Data provided by S. M. Mauer. Biopsies were embedded in paraffin, which results in 
lower MGV compared with resin-embedded tissue.  
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Figure Legend 
Fig. 1. Electron micrograph showing part of the glomerular tuft. Cap. capillary; 
M, mesangium; Pgbm, peripheral glomerular basement membrane (filtration 
surface); Bar, 5 µm 
  
 
 
